TETRALOGIC PHARMACEUTICALS CORP Common Stock

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch TLOG and buy or sell other stocks, ETFs, and their options commission-free!

About TLOG

TetraLogic Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of novel small molecule therapeutics in oncology and infectious diseases. Its products include Birinapant and SHAPE. 

CEO
J. Kevin Buchi, MBA, CPA
CEOJ. Kevin Buchi, MBA, CPA
Employees
11
Employees11
Headquarters
Malvern, Pennsylvania
HeadquartersMalvern, Pennsylvania
Founded
2001
Founded2001
Employees
11
Employees11

TLOG Key Statistics

Market cap
4.89K
Market cap4.89K
Price-Earnings ratio
Price-Earnings ratio
Dividend yield
Dividend yield
Average volume
Average volume
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$0.001
52 Week high$0.001
52 Week low
$0.00
52 Week low$0.00

Stock Snapshot

TETRALOGIC PHARMACEUTICALS CORP Common Stock(TLOG) stock is priced at $0.00, giving the company a market capitalization of 4.89K.

On 2026-07-25, TETRALOGIC PHARMACEUTICALS CORP Common Stock(TLOG) shares started trading at —, with intraday highs of — and lows of —.

Trading volume for TETRALOGIC PHARMACEUTICALS CORP Common Stock(TLOG) stock has reached 0.

Over the past 52 weeks, TETRALOGIC PHARMACEUTICALS CORP Common Stock(TLOG) stock has traded between a high of $0.00 and a low of $0.00.

Over the past 52 weeks, TETRALOGIC PHARMACEUTICALS CORP Common Stock(TLOG) stock has traded between a high of $0.00 and a low of $0.00.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.